Treatment with phosphatidylcholine of patients with nonalcoholic fatty liver disease: a prospective pilot study.
Journal
Minerva gastroenterology
ISSN: 2724-5365
Titre abrégé: Minerva Gastroenterol (Torino)
Pays: Italy
ID NLM: 101777280
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
pubmed:
6
5
2022
medline:
15
12
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is characterized by a complex clinical picture that includes nonalcoholic steatohepatitis and cirrhosis. In the last decades, several studies have shown that NAFLD increases the risk of cardiovascular diseases. In a prospective pilot study, the benefit of treatment with phosphatidylcholine in NAFLD patients has been assessed. Thirty patients with NAFLD were enrolled. All received treatment with phosphatidylcholine (Essentiale After the administration of Essentiale The results of the study indicate that treatment with Essentiale
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is characterized by a complex clinical picture that includes nonalcoholic steatohepatitis and cirrhosis. In the last decades, several studies have shown that NAFLD increases the risk of cardiovascular diseases. In a prospective pilot study, the benefit of treatment with phosphatidylcholine in NAFLD patients has been assessed.
METHODS
METHODS
Thirty patients with NAFLD were enrolled. All received treatment with phosphatidylcholine (Essentiale
RESULTS
RESULTS
After the administration of Essentiale
CONCLUSIONS
CONCLUSIONS
The results of the study indicate that treatment with Essentiale
Identifiants
pubmed: 35511653
pii: S2724-5985.21.03066-7
doi: 10.23736/S2724-5985.21.03066-7
doi:
Substances chimiques
Lecithins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM